Results obtained from biopsy procedures performed with NeoDynamics’ new micro-pulse biopsy system will be analysed and evaluated in a retrospective clinical study.
The micro-pulse technology incorporated in NeoNavia is designed to enable more precise needle insertion, particularly useful in accessing difficult to access lesions whilst also enabling larger tissue samples to be captured. The hope being that the system will contribute to improving breast cancer diagnosis by requiring fewer biopsies as well as obtaining larger and more representative tissue samples. This is crucial for fast and effective individualized treatment decisions to be made and to enable follow-up of tumour response during the course of therapy.
“Being able to accurately position the needle as well as to obtain great quality tissue samples is very valuable. As a breast radiologist, my experience is that the size and representativeness of the tissue sample is crucial in order to be able to make a correct diagnosis and also to give the information needed to choose the right type of treatment, adapted to the individual, taking into account the characteristics of the tumour. For the patient this is of course a great comfort,” says Edward Azavedo, associate professor Karolinska Institute and responsible for the study.
"We are keen to be able to demonstrate the relevance of the new micro-pulse technology for Swedish patients," says Anna Eriksrud, CEO of NeoDynamics. “Even though we are still a small company, we have the ambition to lead the development in precision biopsy and drive change in breast cancer diagnostics. Therefore, we are delighted to see the interest and commitment shown by key opinion leaders in Germany, UK and here in Sweden who are evaluating NeoNavia. We want as many women as possible to benefit from innovative technology that can help improve their potential outcomes,”says Anna Eriksrud, CEO of NeoDynamics.